TRANSCEND FL: High rates of deep and durable responses and sustained survival with liso-cel in patients with R/R FL after three years of follow-up

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

ASH 2025

Lymphoma

ROSEWOOD: Sustained benefits with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in heavily pretreated patients with R/R FL

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

EHA 2025

Leukemia

ZUMA-3: Long-term survival benefit with brexu-cel in patients with R/R B-ALL

Genitourinary Cancer

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

Ann Oncol

Tripathi A, Chen Y, Jarrard DF, Garcia JA, Dreicer R, Liu G, Hussain MH, Shevrin DH, Cooney MM, Eisenberger MA, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Carducci MA, DiPaola RS, Sweeney CJ

doi: 10.1016/j.annonc.2025.08.004

ASH 2025

Lymphoma

BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

EHA 2025

Multiple Myeloma (MM)

RedirecTT-1: Deep and durable responses with talquetamab plus teclistamab in RRMM patients with extramedullary disease

EHA 2025

Lymphoma

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

ROSEWOOD: Sustained benefits with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in heavily pretreated patients with R/R FL

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

ZUMA-3: Long-term survival benefit with brexu-cel in patients with R/R B-ALL

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial

BRUIN: Durable benefits with pirtobrutinib in patients with R/R Waldenström macroglobulinemia

RedirecTT-1: Deep and durable responses with talquetamab plus teclistamab in RRMM patients with extramedullary disease

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM